Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
My Custom Filters
Edit custom filtersResults by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2022 | 1 |
| 2026 | 1 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Cell Metab. 2022 Mar 1;34(3):396-407.e6. doi: 10.1016/j.cmet.2022.02.001.
Cell Metab. 2022.
PMID: 35235774
Free article.
Clinical Trial.
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.
Brakedal B, Skeie GO, Derad C, Alstadhaug KB, Anundskås I, Berven H, Biermann M, Bjørnarå KA, Torres Cleuren YN, Dalbro SEJ, Eidelberg D, Foldnes K, Fortes G, Haugarvoll K, Herlofson K, Hustad E, HogenEsch RI, Johanson GAS, Johnsen SH, Kunszt K, Kverneng S, Labusau A, Lie IH, Lilleng H, Lundervold K, Lundqvist C, Ma Y, McCann A, Njølstad TH, Pihlstrøm L, Riemer F, Rognerud AK, Sheard E, Simonsen AM, Storm E, Svensen M, Toker L, Tunold JA, Dölle C, Friede T, Tzoulis C.
Brakedal B, et al. Among authors: ma y.
JAMA. 2026 Oct 8:e2618828. doi: 10.1001/jama.2026.18828. Online ahead of print.
JAMA. 2026.
PMID: 42848371
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.